Peerview Endocrinology & Diabetes Cme/cne/cpe Audio Podcast

Go online to PeerView.com/DRR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in ophthalmology discusses improving vision outcomes among Spanish-speaking patients with DR and DME, including those residing in rural areas. Upon completion of this CE activity, participants will be able to: Describe the barriers that Spanish-speaking individuals, especially those living in rural areas, frequently encounter when seeking a diagnosis and/or treatment of DR/DME, Construct coordinated care plans with multidisciplinary providers (eg, PCPs, endocrinologists, ophthalmologists, retina specialists) to provide timely diagnosis and treatment for Spanish-speaking patients with DR/DME, especially those residing in rural areas, Discuss the efficacy and safety of anti-VEGF agents in a manner that acknowledges and overcomes patient barriers regarding their use, Implement communication strategies (eg, telehealth, patient education tools, translation

Go online to PeerView.com/AZF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How much do you really know about GLP-1 RAs in the management of T2DM? Test your knowledge about guideline recommendations, current evidence, and strategies to individualize treatment for patients with T2DM using GLP-1 RAs with realistic case-based scenarios. If you need a little help navigating a clinical scenario, a leading endocrinologist will examine current recommendations and evidence for GLP-1 RAs in the management of T2DM, as well as offer his insights on individualizing treatment plans to help patients reach their goals and reduce cardiovascular risks. Think you have all the answers? If so, you’ll be able to take the post-test and claim credit quickly! Upon completion of this CE activity, participants will be able to: Differentiate the therapeutic characteristics beyond glycemic control of GLP-1 RAs from other glucose-lowering agents, Construct individualized treatment

Go online to PeerView.com/FCW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in hepatology provides practical guidance across the spectrum of care from screening and diagnosis to management of patients with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). Upon completion of this activity, participants should be better able to: Discuss the epidemiology and disease burden of NAFLD/NASH, Describe the relationship between NAFLD/NASH and cardiovascular disease, Assess current and emerging treatments for NASH in the context of mechanism of action (eg, ability to target various metabolic, inflammatory, and fibrotic pathways involved in disease progression) and current clinical evidence (eg, impact on fibrosis and cardiovascular risk; safety)

Go online to PeerView.com/VUG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in pediatric growth hormone deficiency (pGHD) discusses the latest advances in treatment and patient-centered approaches to care. Upon completion of this activity, participants should be better able to: Identify appropriate pediatric candidates for growth hormone (GH) therapy based on approved indications, current recommendations, and relevant diagnostic test results, Evaluate evidence regarding the clinical characteristics (eg, efficacy, safety and tolerability, ease of administration, dosing frequency) of available and emerging GH therapies, Individualize pediatric GH therapy to include efforts that address patient needs and preferences, such as personalized dosing, therapeutic monitoring, and assistance with care transitions.

Go online to PeerView.com/WBN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Obesity is a complex chronic disease that can cause serious health complications. Current guidelines advocate for the use of multiple interventions to address the genetic, behavioral, and metabolic factors that contribute to insufficient weight loss or weight regain. Weight-loss pharmacotherapy is a recommended approach with distinct mechanisms of action that can affect different aspects of obesity pathophysiology. In this activity, based on a recent live web broadcast, leading experts examine the pathophysiology of obesity, focusing on metabolic adaptation and the role of GLP-1 in energy consumption and expenditure and review the latest evidence for GLP-1–based agents. The panel also discusses clinically relevant patient scenarios to offer practical guidance on identifying ideal candidates for weight-loss medications and integrating these medications into individualized treatme

Go online to PeerView.com/CMG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Intravitreal treatments have advanced rapidly to become the mainstay of therapy for DR/DME. Anti-VEGF agents and corticosteroid implants have demonstrated efficacy for reducing vision loss from DR/DME and may be administered adjunctively to laser photocoagulation. Increasingly, studies comparing these treatments in combination, in sequence, or in head-to-head trials are becoming available, helping to refine decisions regarding the right therapy for the right patient at the right time. Additionally, new intravitreal treatments offer the potential of even higher efficacy, greater safety, or longer intervals between retreatments. Join our panel of noted retina specialists for an engaging discussion of emerging agents, including a review of recent reported clinical trials and their implications for advancing patient-centered care for DR/DME. The expert dialogue will be complemented